Recruiting
Phase 1

BMS-986435

Sponsor:

Bristol-Myers Squibb

Code:

NCT07226817

Conditions

Healthy Volunteers

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

BMS-986435

Study Details

Brief summary:

This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.

Conditions

Healthy Volunteers

Study ID

NCT07226817

Start date

Nov 12, 2025

Status verified date

Aug, 2026

Completion date

Dec 17, 2026

Anticipated

Primary completion date

Dec 17, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Inclusion Criteria

  • Participants must have a body weight of ≥ 45 kg and BMI between 18 and 32 kg/m2, inclusive
  • Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory assessments
  • Participants must have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment
  • Other protocol-defined Inclusion/Exclusion criteria apply

Study Design

Enrollment

240 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment A

experimental: Treatment B

experimental: Treatment C

experimental: Treatment D

experimental: Treatment E

experimental: Treatment F

experimental: Treatment G

experimental: Treatment H

experimental: Treatment I

experimental: Treatment J

experimental: Treatment K

experimental: Treatment L

Interventions

BMS-986435

Specified dose on specified days

Primary outcome measure

  • Maximum observed concentration (Cmax) [ Time Frame: Up to Day 28 ]
  • Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) [ Time Frame: Up to Day 28 ]
  • Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) [ Time Frame: Up to Day 28 ]

Central Contacts and Locations

Central contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286Clinical.Trials@bms.com

Locations

Quotient Miami

Recruiting

Miami, Florida, United States, 33126

More Information

Sponsor

Bristol-Myers Squibb

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-08-12.